%0 Journal Article
%T Co-Morbidities as Predictors of Airflow Limitation among Smokers in England
%A Iman Hesso
%A Reem Kayyali
%A Roshan Siva
%A Yusur Hassan
%J Archive of "Pharmacy: Journal of Pharmacy Education and Practice".
%D 2018
%R 10.3390/pharmacy6020045
%X The prevalence of co-morbidities among patients with Chronic Obstructive Pulmonary Disease (COPD) is well documented in the literature. Therefore, this pilot study aimed to identify whether co-morbidities screening would enhance COPD case-finding. Smoking patients were approached at Croydon University Hospital and two local community pharmacies (CPs). Their co-morbidities, respiratory symptoms, smoking pack-years and exercise capacity were collected. Airflow limitation was determined using handheld spirometry (COPD-6) device. The prevalence of airflow limitation was 42% (n = 21/50). The main identified predictors of airflow limitation were: co-morbidities (OR = 9, CI: 1.04¨C77.81, p = 0.025), respiratory symptoms (OR = 33.54, CI: 1.06¨C11.77, p = 0.039) and smoking history of ¡Ý20 pack-years (OR = 3.94, CI: 1.13¨C13.64, p = 0.029). CPs were the main location for case-finding. This study demonstrated the need to screen for co-morbidities for COPD case-finding within CPs
%K Chronic Obstructive Pulmonary Disease (COPD)
%K airflow limitation
%K co-morbidities
%K smoking
%K primary care
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025281/